Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
LN-020 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
LN-020: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
VBI-2601 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
VBI-2601: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
CYL-02 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
CYL-02: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
PB-1802 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
PB-1802: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
ACI-35.030 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
ACI-35.030: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
FG-001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
FG-001: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Opemalirsen Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Opemalirsen: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
YH-12852 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
YH-12852: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Itacitinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Itacitinib: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Escherichia coli/Shigella oral vaccine (Eveliqure Biotechnologies) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Escherichia coli/Shigella oral vaccine (Eveliqure Biotechnologies): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licen
9 min read
Lansoprazole/Omeprazole Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Lansoprazole/Omeprazole: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Casdozokitug Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Casdozokitug: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.